Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

1991 • 5,979 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Histological Grading and Prognosis in Breast Cancer

1957 • 2,897 citations

Diseases of the Breast

1971 • 1,803 citations

Pathological prognostic factors in breast cancer

1999 • 1,676 citations

The urokinase-type plasminogen activator system in cancer metastasis: A review

1997 • 1,561 citations

Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials

1995 • 978 citations

Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials

1996 • 789 citations

Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

1996 • 749 citations

Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy

1997 • 391 citations

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1993 • 367 citations

Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast Cancer

1992 • 277 citations

Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer

1993 • 265 citations

Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

1998 • 241 citations

Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer

1991 • 236 citations

Steroid receptors and other prognostic factors in primary breast cancer.

1988 • 227 citations

Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer

1995 • 161 citations

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

1998 • 124 citations

The urokinase plasminogen activator system as a novel target for tumour therapy

2000 • 111 citations

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

1998 • 94 citations

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

1999 • 91 citations

Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse

1999 • 90 citations

Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial

1990 • 78 citations

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop

1996 • 71 citations

More flexible sequential and non-sequential designs in long-term clinical trial

1984 • 66 citations

Immunohistochemical Detection of Hormone Receptors in Breast Carcinomas (ER-ICA, PgR-ICA): Prognostic Usefulness and Comparison with the Biochemical Radioactive-Ligand-Binding Assay (DCC)

1994 • 43 citations

Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 • 28 citations

Cited By (0)

Loading...